ProPharma's RCO & AI: Breaking Barriers in Clinical Trial Diversity
Diverse groups of participants in clinical trials can be the key to examining how different individuals respond to a treatment. Researchers must identify variations in treatment responses across diverse populations to gain a greater understanding of interactions across various patient characteristics, including genetic, physiological, and environmental differences. Additionally, advances in the field of precision medicine are reliant on tailored treatments for individual patients based on their genetic biomarkers and lifestyle.
In this whitepaper, ProPharma discusses how our RCO model provides bespoke solutions to organizations, helping them address diversity in clinical trials, including key factors such as:
- Mistrust of the medical system and cognitive bias
- Limited access and awareness
- Geographical barriers
- Language and cultural barriers
- Study design and underrepresentation in trial recruitment
Learn more about how ProPharma is utilizing AI technology to assist in mitigating the lack of diversity in clinical trials, helping companies address health disparities, and promoting health equity. Complete our form to get instant access to the whitepaper.
Related Resources
The Cost of Poor Project Management
Project Management isn’t for the faint of heart. There is a shockingly high rate of project failure… but on the other hand, great project management can be a key differentiator that leads a company...
Successfully Passing MHRA Inspections for Overseas Manufacturing Sites
ProPharma offers GMP and GDP compliance services from clinical development to commercial distribution of the products' lifecycle. ProPharma’s Compliance and Quality team completed the first on-site...
Navigating the Generic Drug Application and Approval Process
Navigating the generic drug application and approval process can be challenging. From pre-filing through post-approval, find out exactly what needs to be done for your Abbreviated New Drug...